Bacterial Meningitis Epidemiology and Vaccination
This timely collection of expert papers draws attention to the global burden of meningitis and the challenges faced by the WHO's roadmap to defeat meningitis by 2030. The three main goals of the meningitis roadmap are to eliminate epidemics of bacterial meningitis, reduce cases and deaths from...
Saved in:
Other Authors: | |
---|---|
Format: | Electronic Book Chapter |
Language: | English |
Published: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
Subjects: | |
Online Access: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000naaaa2200000uu 4500 | ||
---|---|---|---|
001 | doab_20_500_12854_76735 | ||
005 | 20220111 | ||
003 | oapen | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 20220111s2021 xx |||||o ||| 0|eng d | ||
020 | |a books978-3-0365-1808-4 | ||
020 | |a 9783036518077 | ||
020 | |a 9783036518084 | ||
040 | |a oapen |c oapen | ||
024 | 7 | |a 10.3390/books978-3-0365-1808-4 |c doi | |
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a GP |2 bicssc | |
072 | 7 | |a PS |2 bicssc | |
100 | 1 | |a Stuart, James M. |4 edt | |
700 | 1 | |a Stuart, James M. |4 oth | |
245 | 1 | 0 | |a Bacterial Meningitis |b Epidemiology and Vaccination |
260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
300 | |a 1 electronic resource (274 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
520 | |a This timely collection of expert papers draws attention to the global burden of meningitis and the challenges faced by the WHO's roadmap to defeat meningitis by 2030. The three main goals of the meningitis roadmap are to eliminate epidemics of bacterial meningitis, reduce cases and deaths from vaccine-preventable bacterial meningitis, and reduce disability and improve quality of life after meningitis of any cause. This book includes a wide range of original research and reviews on epidemiology and vaccination of bacterial meningitis that have direct relevance to advancing the goals of the roadmap. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Research & information: general |2 bicssc | |
650 | 7 | |a Biology, life sciences |2 bicssc | |
653 | |a meningitis | ||
653 | |a child mortality | ||
653 | |a neonatal sepsis | ||
653 | |a global health | ||
653 | |a global health estimates | ||
653 | |a modelling | ||
653 | |a Streptococcus pneumoniae | ||
653 | |a Haemophilus influenzae | ||
653 | |a Neisseria meningitidis | ||
653 | |a bacterial meningitis | ||
653 | |a S. pneumoniae | ||
653 | |a N. meningitidis | ||
653 | |a H. influenzae | ||
653 | |a S. agalactiae | ||
653 | |a conjugate vaccines | ||
653 | |a post-vaccine surveillance | ||
653 | |a vaccine | ||
653 | |a Africa | ||
653 | |a mathematical modelling | ||
653 | |a susceptibility | ||
653 | |a invasive bacterial infections | ||
653 | |a complement | ||
653 | |a genetic factors | ||
653 | |a Streptococcus agalactiae | ||
653 | |a group B streptococci | ||
653 | |a capsule | ||
653 | |a meningococcal group | ||
653 | |a nongroupable | ||
653 | |a meningococcal carriage | ||
653 | |a invasive meningococcal disease | ||
653 | |a meningococcal urethritis | ||
653 | |a neonatal infections | ||
653 | |a epidemiology | ||
653 | |a antibiotic resistance | ||
653 | |a etiologic diagnosis | ||
653 | |a enterovirus | ||
653 | |a group B Streptococcus | ||
653 | |a neurological sequelae | ||
653 | |a hearing loss | ||
653 | |a seizure | ||
653 | |a epilepsy | ||
653 | |a hydrocephalus | ||
653 | |a focal neurological deficit | ||
653 | |a corticosteroid | ||
653 | |a dexamethasone | ||
653 | |a invasive pneumococcal disease | ||
653 | |a pneumococcal conjugate vaccines | ||
653 | |a serotypes | ||
653 | |a vaccine impact | ||
653 | |a pneumococcal meningitis | ||
653 | |a serotype distribution | ||
653 | |a PCV impact | ||
653 | |a global | ||
653 | |a meta-analysis | ||
653 | |a surveillance | ||
653 | |a meningococcus | ||
653 | |a pneumococcus | ||
653 | |a Hib | ||
653 | |a group B streptococcus | ||
653 | |a conjugate vaccine | ||
653 | |a rapid diagnostic test | ||
653 | |a national reference laboratory | ||
653 | |a cerebrospinal fluid | ||
653 | |a Niger | ||
653 | |a Burkina Faso | ||
653 | |a tuberculosis | ||
653 | |a tuberculous meningitis | ||
653 | |a TBM | ||
653 | |a children | ||
653 | |a impact of Hib conjugate vaccine | ||
653 | |a Hia | ||
653 | |a NTHi | ||
653 | |a burden | ||
653 | |a social and economic costs | ||
653 | |a WHO meningitis roadmap | ||
653 | |a disability | ||
653 | |a n/a | ||
856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/4184 |7 0 |z DOAB: download the publication |
856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/76735 |7 0 |z DOAB: description of the publication |